Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis: A double-blind, randomized, placebo-controlled study

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 53, Issue 9, 1998, Pages 857-862

  Giede Tuch, C ^a   Westhoff, M ^b   Zarth, A ^b  

^a NONE   (Germany)

^b NONE   (Germany)

Author keywords

Allergic conjunctivitis; Azelastine; Histamine H1 receptor blockers; Human; Therapeutic use

Indexed keywords

AZELASTINE;

ADULT; ALLERGIC CONJUNCTIVITIS; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; LACRIMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEASONAL VARIATION; TASTE DISORDER; TOPICAL DRUG ADMINISTRATION;

EID: 0031684987     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.1998.tb03991.x     Document Type: Article

References (13)

1. Friedlaender MH. Conjunctivitis of allergic origin: clinical presentation and differential diagnosis. Surv Ophthalmol 1993;38 Suppl July, August: 105-14.
2. Abelson MB, Schaeffer K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv Ophthalmol 1993;38 Suppl July, August:115-32.
3. Ciprandi G, Buscaglia S, Canonica GW. Management of allergic conjunctivitis. Clin Immunother 1996;5:374-91.
4. Abelson MB, Weintraub D. Levocabastine eye drops: a new approach for the treatment of acute allergic conjunctivitis. Eur J Ophthalmol 1994;4:91-101.
5. McTavish D, Sorkin EM. Azelastine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1989;38:778-800.
6. Gastpar H, Aurich R, Petzold U, Virnkaes C. Azelastin-Nasenspray zur topischen Behandlung allergischer Rhinopathien. Atemw Lungenkrkh 1993;19:148-54.
7. Horak F, Berger U, Menapace R, Schuster N. Quantification of conjunctival vascular reaction by digital imaging. J Allergy Clin Immunol 1996;98:495-500.
8. Tinkelman D, Rupp G, Kaufman H, Pugely J, Schultz N. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38 Suppl July, August:133-40.
9. 1 antagonist in patients with allergic conjunctivitis. Allergy 1985;40:491-6.
10. Ciprandi G, Buscaglia S, Catrullo A, et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert antiallergic activity. Clin Exp Allergy 1997;27:182-91.
11. Ciprandi C, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic-activity. J Allergy Clin Immunol 1996;98:1088-96.
12. Howarth PH. A review of the tolerability and safety of levocabastine eye drops and nasal spray. Implications for patient management. Mediators Inflamm 1995;4:S26-S30.
13. van Wijk RG. Treatment of allergic rhinoconjunctivitis: a review of the role of topical levocabastine. Mediators Inflamm 1995;4:S31-8.